en ENGLISH
eISSN: 2719-3209
ISSN: 0023-2157
Klinika Oczna / Acta Ophthalmologica Polonica
Bieżący numer Archiwum Filmy Artykuły w druku O czasopiśmie Suplementy Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury
 
1/2022
vol. 124
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
Artykuł oryginalny

The influence of escitalopram therapy on macular function in patients with major depression – preliminary report

Wojciech Lubiński
1
,
Hanna Grabek-Kujawa
1
,
Ewa Dańczura
2
,
Jolanta Kucharska-Mazur
2
,
Jerzy Samochowiec
2
,
Maciej Mularczyk
3

1.
II Clinic of Ophthalmology, Pomeranian Medical University, Szczecin, Poland
2.
Chair and Clinic of Psychiatry, Pomeranian Medical University, Szczecin, Poland
3.
Chair and Department of Human and Clinical Anatomy, Pomeranian Medical University, Szczecin, Poland
KLINIKA OCZNA 2022, 124, 1: 25–30
Data publikacji online: 2022/03/25
Plik artykułu:
- KO-00319_EN.pdf  [0.33 MB]
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

INTRODUCTION

Major depression is a chronic, recurrent mental disease with the highest lifetime prevalence among major psychiatric disorders. The World Health Organization expects that, by 2030, MD will become the second most common cause of disability and burden of disease [1]. In the treatment of MD, antidepressant medications remain a mainstay especially for cases with moderate to severe depression, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrena-line reuptake inhibitors (SNRIs). Nowadays, most clinical guidelines recommend the new generation of antidepressants as the first-line treatment for MD [2, 3]. Escitalopram, an S-enantiomer of racemic citalopram, is an SSRI and also has a modulatory effect at an allosteric binding site of the serotonin transporter protein [4, 5]. It has been shown that escital-opram is effective for MD treatment and presents better efficacy and tolerability to other SSRIs and other antidepressants [4-6].
For the evaluation of the therapeutic response to medication in patients with major depression objective biomarkers of depression could be very helpful. One possible candidate in this case might be the pattern electroretinogram (PERG), be-cause this test records the macular photoreceptors’ function as well as the retinal ganglion cells’ response. The retinal gan-glion cells indirectly examine the brain activity because of their anatomical and functional properties [7].
To date, only one study’s results have been published in the literature describing the effect of antidepressive therapy on ganglion cells function measured by PERG [8]; reduced PERG-contrast gain normalized after antidepressive therapy, suggest-ing that this test can serve as a state marker of depression. Also there can be found reports of PERG scores in another psy-chiatric disorder where SSRIs are used – schizophrenia. Bernardin et al. observed a significant increase of the peak time of P50 and N95 waves in schizophrenia patients compared with controls [9]. To confirm the potential value of PERG examina-tion in objective estimation of the therapeutic response to medication, we decided to perform in a newly recognized, un-treated group of patients with major depression the ISCEV transient PERG before and after escitalopram treatment.

MATERIAL AND METHODS

Before treatment, in 21 newly, diagnosed (42 eyes) patients (mean age: 46.4 ±11.6 years) with major depression (MD), and in 29 (58 eyes) age- and sex-matched healthy controls (mean of age:46.3 ±10.4 years) the following examinations were performed: the best distance corrected visual acuity (Snellen Table), intraocular pressure, biomicroscopy of anterior and posterior segment of the eye and macular structure (SD-OCT-Zeiss). In the MD group, before and after 4 weeks of escitalopram treatment a pattern electroretinogram (PERG-ISCEV standards) [10] was registered. The amplitudes of P50 and N95 waves, as well as peak time of the P50 wave, were measured. Values of all parameters were compared with age- and sex-matched healthy controls.
Written informed consent was obtained from all participants. The study was approved by the local ethics committee of Pomeranian Medical University (PMU) in Szczecin.
Patients with MD were referred from the Department of Psychiatry of PMU with a major depressive episode according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders-DSM-IV) and were assessed psychometrically with the Hamilton Depression Rating scale (HAMD ) before and after escitalopram treatment (Table I).
Patients with other psychiatric disorders, as well as ocular and systemic diseases with a known influence on retinal function, were excluded.

Statistical analysis

The obtained data of PERG parameters from the MD group before and after escitalopram treatment, and from controls, were analyzed statistically. The assumption of normality was checked using the Shapiro-Wilk test. In reference to normality tests, the norm ranges have been determined based on the values of parameters from the control group. In the case of the normal distribution of the variables, the range of the norm was between –2SD and +2SD, in the absence of normality the range of the norm was between 2.5 and 97.5 percentiles. The values of the PERG parameters before and after treatment and in relation to the control were compared. Depending of the variable distribution, two different tests were used, paramet-ric or nonparametric, Student’s t-test, Wilcoxon test) or the Mann-Whitney U test, respectively. An analysis of the correlation (Spearman rank correlation test) between pre- and post treatment changes of PERG parameters and depression severity (measured using the Hamilton Depression Rating Scale – HAMD) was achieved. Results were considered as statistically signif-icant with p < 0.05.

RESULTS

In the study group and controls the clinical results were normal and were as follows: the best distance corrected visual acuity − 1.0 (both groups), intraocular pressure (16.7 ±1.2 versus 16.2 ±1.2 mmHg)- between normal limits, biomicroscopy of anterior and posterior segment of the eye – normal, normal macular structure (cube average thickness- 280.4 ±13.5 ver-sus 282.4 ±8.8 µm), retinal nerve fiber layer thickness – 93.6 ±11.1 µm versus 95.0 ±8.2 µm.
There was no statistical difference in age between MD patients and controls (p > 0.5; Table II).
Before treatment a significant reduction of mean amplitudes of P50 and N95 waves in comparison to the control group was obtained as well as a non-significant increase of PTP50.
Normal range of PERG parameters is presented in Table III. The Shapiro-Wilk test was used to check normal distribution of particular parameters.
Table IV shows the frequency of abnormal results of PERG parameters before and after escitalopram treatment of MD pa-tients (n = 42 eyes) in relations to normal values presented in Table III.
After escitalopram treatment, the most prominent feature was disappearance of prolonged PTP50 seen initially (Figure 1).
In the PERG test, after treatment, significant shortening of PTP50 was achieved (p = 0.03). The amplitudes of AP50 and AN95 did not change significantly after treatment (p = 0.55, p = 0.73, respectively).
Figure 2 shows PERG results of an MD patient with significant shortening of PTP50 after escitalopram treatment in com-parison to the peak time of theP50 wave before treatment.
In the MD group after treatment a significant reduction of HAMD score was detected in comparison to the initial value (26.4 ±6.6 versus 15.3 ±4.9; p = 0.0001*).
Correlation analysis of PERG parameters and HAMD score before and after treatment and after treatment (n = 21 pa-tients) is shown in Table V.
Correlations between analyzed PERG parameters and HAMD score before treatment and after treatment were not found (Spearman rank test; p > 0.05).
After escitalopram treatment, in four MD patients improvement from severe to mild depression and in one patient from severe to normal was achieved. In these patients a statistically significant positive correlation between reduction of HAMD score and PTP50 was observed (p = 0.04).

DISCUSSION

Our study results suggest that in patients with MD treated with escitalopram, the improvement of macular cone system function can be registered and manifested by significant shortening of the PTP50 wave (Figures 1, 2). The amplitudes of P50 and N95 waves did not change significantly and indicate that ganglion cells function remains abnormal. In the monoamine deficiency hypothesis, MD pathophysiology is connected with a deficit in neurotransmission of serotonin, norepinephrine and dopamine [12-14]. Serotonin is detected in the mammalian retina and is involved in retinal neurotransmission. Anatom-ical studies demonstrated that mammalian retinas receive inputs from the brain via retinopetal axons emerging from the optic nerve [15]. This chemical messenger is targeted by a broad range of antidepressant drugs such as escitalopram mediating the serotoninergic neurotransmission. Tryptophan hydroxylase 1 (Tph1) is responsible for serotonin synthesis in the retina [16].The levels of endogenous serotonin in mammalian retinas are relatively low, approximately 10% of the levels of an amacrine cell neurotransmitter, dopamine. Low levels of endogenous serotonin suggest that this neurotransmitter is used by a sparse population of retinopetal axons rather than amacrine cells. Since serotonin receptors are detected not only in the ganglion cells but also in cone photoreceptors (5-HT2A receptor) in mammalian retinas [17], it may be possible that stimulation of the serotoninergic pathway can impact the PERG recording, as was shown in escitalopram responder MD pa-tients in our study. It is commonly know that a change of the PTP50 wave in PERG examination is associated with dysfunc-tion of the outer retinal layer (cone photoreceptors, bipolar cells) of the macular region [18]. It is also known that the electroretinographic photopic b-wave originates from bipolar cells but after cone photoreceptor stimulation. We think that in the present study the prolonged PTP50 albeit not significant in MD patients in comparison to controls is a result of the reduced level of serotonin in the brain (Table II). It was demonstrated previously that patients with depressive symp-toms have increased photopic b-wave implicit time [19]. From another study it is known that Tph2 knockin (Tph2-K1) mice have reduction of 80% in brain serotonin and express depression-related behavioral abnormalities [20] and are characterized by an increase of photopic ERG b-wave implicit time [21]. The genetic mutation of Tph2-K1 mice does not affect the serotonin content in the retina. It suggests that a decrease in brain serotonin might be sufficient to modify the photopic b-wave implicit time via retinopetal axons. A longer photopic b-wave implicit time was also observed during depressive episodes in seasonal affective disorder [22]. Consequently, increase of serotonin level in the brain after escitalopram treatment was a cause of shortening of the PTP50 wave in PERG examination, which was shown for the first time in our study (Table IV, Figures 1, 2). It remains unsolved why the increase of serotonin level in the brain after treatment did not change reduced amplitudes of P50 and N95 waves seen initially which are mainly of ganglion cell origin. One possible explanation is the fact that alt-hough retinopetal axons terminate in the inner retina, their targets are often in the outer retina where serotonin receptors are located (photoreceptor terminals). Additionally, the probable lack of the increase of retinal serotonin after escitalopram treatment might also be responsible for unchanged retinal ganglion cell function.
After escitalopram application in all patients a decrease of HAMD score was noted and indicates efficacy of this drug in MD treatment. In the whole group HAMD score improvement was not correlated with PERG parameters (Table V). When patients were analyzed separately, in 5 MD patients in whom improvement from severe to mild depression or normal was detected, a statistically significant positive correlation between reduction of HAMD score and PTP50 was observed (p = 0.04). The data we obtained are in line with previous observations [9] that PERG can be an important method for assessing re-sponses to treatment in major depression. There are not enough data to say why PTP50 is an indicator of improvement. According to observations by Bulb et al. [28], higher sensitivity of depressive symptoms correlates with higher VEP ampli-tude, but the PERG signal is more sensitive. As the PERG study on depression is a new area, there is no information on PTP50 as an indicator of the severity of depression. It is worth noting that the observations we have made concern a small group.
In conclusion, our study results suggest that in patients with major depression, the improvement of bioelectrical macular cone system function was detected after escitalopram treatment. The ISCEV PERG has a potential value to be useful, objec-tive test in estimation of the treatment success. Investigations on a larger group of patients are necessary to confirm our promising initial results. Additional studies are also necessary to clarify the interaction between neurotransmitters in the retina and in the brain and how they relate to the pathogenesis of MD.

DISCLOSURE

The authors declare no conflict of interest.

References

1. Mathers C, Fat DM, Boerma J. The Global Burden of Disease: 2004 Update. 2008;World Health Organization, [DB/OL] http://www.who. int/healthinfo/global_burden_disease/GBD_report_2004update_full. pdf?ua=1.
2. Davidson J. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71: e04.
3. Gelenberg A. A review of the current guidelines for depression treatment. J Clin Psychiatry 2010; 71: e15-15.
4. Baldwin DS. Escitalopram: efficacy and tolerability in the treatment of depression. Hosp Med 2002; 63: 668-671.
5. Kasper S, Baldwin DS, Larsson Lonn S, et al. Superiority of escitalopram to paroxetine in the treatment of depression. Eur Neuropsycho-pharmacol 2009;19: 229-237.
6. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major de-pressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007; 23: 401-416.
7. Schwitzer T, Achwan R, Bubl E, et al. Looking into the brain through the retinal ganglion cells in psychiatric disordres; a review of evidences. Prog Neuropsychopharmacol Biol Psychiatry 2017; 76: 155-162.
8. Bubl E, Ebert D, Kern E, et al Effect of antidepressive therapy on retinal contrast processing in depressive disorder. Br J Psychiatry 2012; 201: 151-158.
9. Bernardin F, Schwitzer T, Angioi-Duprez K, et al. Retinal ganglion cells dysfunctions in schizophrenia patients with or without visual halluci-nations. Schizophr Res 2020; 219: 47-55
10. Bach M, Brigell MG, Hawlina M, et al. ISCEV standard for clinical pattern electroretinography (PERG) – 2012 update. Doc Ophthalmol 2013; 126: 1-7.
11. Zimmermann M, Martinez JH, Young D, et al. Severity classification on the Hamilton depression rating scale. J Affect Disord 2013; 2: 384-388.
12. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008; 358: 55-68.
13. Maan het Rot, S.J. Mathew, D.S. Charney. Neurobiological mechanisms in major depressive disorder. CMAJ Can Med Assoc J 2009; 180: 305-313
14. Hamon M, P. Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psy-chiatry 2013; 45: 54-63.
15. Gastinger MJ, Tian N, Horvath T, Marshak DW. Retinopetal axons in mammals: emphasis on histamine and serotonin. Curr Eye Res 2006; 31: 655e667.
16. Liang J, Wessel JH 3rd, Iuvone PM, et al. Diurnal rhythms of tryptophan hydroxylase 1 and 2 mRNA expression in the rat retina. Neuroreport 2004; 15: 1497-1500.
17. Pootanakit K, Prior KJ, Hunter DD, Brunken WJ. 5-HT2a receptors in the rabbit retina: potential presynaptic modulators. Vis Neurosci 1999; 16: 221-230.
18. Holder GE. Pattern Electroretinography (PERG) and an Integrated Approach to Visual Pathway Diagnosis. Prog Retin Eye Res 2001; 20: 531-561.
19. Fountoulakis KN, Fotiou F, Iacovides A, Kaprinis G. Is there a dysfunction in the visual system of depressed patients? Ann Gen Psy-chiatry 2005, 4: 1-10.
20. Beaulieu JM, Zhang X, Rodriguiz RM, et al. Role of GSK3 beta in behavioral abnormalities in-duced by serotonin deficiency. Proc Natl Acad Sci U S A 2008; 105: 1333-1338.
21. Lavoie J, Illiano P, Sotnikova TD, et al. The electroretinogram as a biomarker of central dopamine and serotonin: potential relevance to psychiatric disorders . Biol Psychiatry 2014, 75: 479-486.
22. Lavoie MP, Lam RW, Bouchard G, et al. Evidence of a biological effect of light therapy on the retina of pa-tients with seasonal affective disorder. Biol Psychiatry, 2009; 66: 253-258.
23. Nightingale S, Mitchell KW, Howe JW. Visual evoked cortical potentials and pattern electroretinograms in Parkinson’s disease and control subjects. J Neurol Neurosurg Psychiatry 1986; 49: 1280-1287.
24. Garcia-Martin E, Rodriguez-Mena D, Satue M, et al. Electrophysiology and optical coherence tomography to evaluate Parkinson dis-ease severity. Invest Ophthalmol Vis Sci 2014; 55: 696-705.
25. Hamilton JP, Chen G, Thomason ME, et al. Investigating neural primacy in major depressive disorder: multivariate Granger causality analysis of resting-state fMRI time-series data. Mol Psychiatry 2011; 16: 763-772.
26. Saijo T, Takano A, Suhara T, et al. Electroconvulsive therapy decreases dopamine D2 receptor binding in the anterior cingulate in pa-tients with depression: a controlled study using positron emission tomography with radioligand [11C]FLB 457. J Clin Psychiatry 2010; 71: 793-799.
27. Pei L, Li S, Wang M, et al. Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med 2010; 16: 1393-1395.
28. Bubl E, Kern E, Ebert D, et al. Retinal dysfunction of contrast processing in major depression also apparent in cortical activity. Eur Arch Psychiatry Clin Neurosci 2015; 265: 343-350.
facebook linkedin twitter
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.